Deals


  • A sign showing the Takeda Oncology logo.
    Image attribution tooltip
    Jacob Bell

    Takeda pays $400M to buy into Hutchmed’s colorectal cancer drug

    The deal is the second big licensing deal Takeda has signed in as many months and gives the company rights to a drug Hutchmed began submitting to U.S. regulators in December.

    By Jan. 23, 2023
  • A screenshot of BioPharma Dive editor Chris Newman speaking with three biotech executives during an online webinar
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive

    3 biotech executives on the year ahead: deals, drug pricing and the down market

    “What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

    By Jan. 19, 2023
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • A photograph of Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Courtesy of Editas Medicine

    Editas, in next restructuring step, to sell cell therapy work to Shoreline

    Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology. 

    By Jan. 19, 2023
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Sun Pharma to buy Concert, pick up experimental hair loss drug

    Sun intends to submit the drug, called deuruxolitinib, for U.S. approval in the first half of this year, following in the footsteps of similar therapies from Pfizer and partners Eli Lilly and Incyte.

    By Jan. 19, 2023
  • A 3D illustration of cancer cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images

    Leap Therapeutics to buy Flame Biosciences in all-stock deal

    The deal gives Leap several early-stage drug candidates, including an antibody targeting the protein Claudin 18.2, which has lately drawn several other biotech companies’ interest.

    By Jan. 17, 2023
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

    Arrakis CEO Michael Gilman discussed platform companies’ central challenge, while Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted at greater dealmaking to come for their companies.

    By , , Jan. 10, 2023
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

    AstraZeneca is acquiring CinCor Pharma, while Ipsen and Chiesi announced deals to buy rare disease drugmakers Albireo and Amryt Pharma, respectively. 

    By Jan. 9, 2023
  • Image attribution tooltip
    Viktor Chebanenko via Getty Images

    Ensoma buys a startup to advance ‘in vivo’ cell therapy work

    The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.

    By Jan. 6, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images

    Kenvue, J&J’s consumer health unit, files for an IPO in step toward split

    The IPO, which one estimate said could raise as much as $5 billion, is likely to be one of the largest new stock offerings in recent years.

    By Jan. 5, 2023
  • A building with the Moderna logo.
    Image attribution tooltip
    Moderna

    Moderna, becoming a buyer, acquires a synthetic biology specialist

    The biotech said its first acquisition, an $85 million purchase of Japanese company OriCiro Genomics, will hand it better tools to make a key building block of messenger RNA.

    By Kristin Jensen • Jan. 4, 2023
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Lilly pays $75M to widen RNA editing deal with ProQR

    The expanded deal triples the amount of money the biotech could eventually receive from Lilly and adds several more neurological disease drug targets. 

    By Dec. 22, 2022
  • Image attribution tooltip
    Jacob Bell

    Jazz pays Zymeworks $325M for HER2 drug rights after positive data

    Two months after signing a deal with Zymeworks, Jazz exercised an option for the drug after it showed potential in treating biliary tract cancer.

    By Dec. 21, 2022
  • Two employees walk down a hallway in Gilead's Kite cell therapy unit.
    Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma

    Gilead buys Tmunity, cozying up to a CAR-T pioneer

    Tmunity, a private biotech co-founded by cell therapy researcher Carl June, offers Gilead a slate of experimental programs, a technology platform and an alliance with the University of Pennsylvania. 

    By Dec. 20, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen

    Roche, Biogen sign royalty deal for late-stage lymphoma drug

    Roche will pay royalties to Biogen on glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus.

    By Updated Dec. 26, 2022
  • Lilly partners with Sosei to develop drugs aimed at a key family of proteins

    The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

    By Dec. 16, 2022
  • Portrait of Jeb Keiper, CEO of Nimbus Therapeutics.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics
    Q&A // Emerging biotech

    Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup

    Days after inking one of the largest deals for an unapproved drug, the CEO spoke with BioPharma Dive about the company’s unusual origins and decision to remain private — for now. 

    By Dec. 16, 2022
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK gives Wave a lift with genetic medicine deal

    A four-year agreement between the companies comes with $170 million in cash and equity for Wave, which in recent years has dealt with clinical setbacks.

    By Kristin Jensen • Dec. 14, 2022
  • A person in an office uses a virtual reality headset to examine a 3D model on a computer screen.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics

    Takeda to pay $4B for Nimbus’ TYK2 drug

    In one of the largest single-asset deals in recent history, the Japanese pharma is acquiring a medicine Nimbus claims can top Bristol Myers’ recently approved psoriasis drug Sotyktu.  

    By Dec. 13, 2022
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.

    Amgen to buy Horizon in year’s biggest biotech deal

    After outlasting rival suitors Sanofi and J&J in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.

    By Updated Dec. 12, 2022
  • Two employees walk down a hallway in Gilead's Kite cell therapy unit.
    Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma

    Gilead buys into multiple myeloma cell therapy with Arcellx deal

    The company is paying Arcellx $225 million, on top of a $100 million equity investment, for rights to a CAR-T therapy that’s currently in mid-stage testing as a treatment for the blood cancer.

    By Dec. 9, 2022
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex invests in a rare disease drug and its developer

    The big biotech is paying Entrada Therapeutics $250 million upfront to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline.  

    By Dec. 8, 2022
  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images

    TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout

    After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal.

    By Dec. 5, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    J&J drops out of hunt for Horizon, leaving Sanofi and Amgen to bid

    The two remaining suitors said they would make cash bids if they move forward with offers, for which they must declare “firm intent” by Jan. 10 under Irish takeover rules.

    By Dec. 5, 2022
  • Pfizer, Roivant set up new company around inflammation drug

    The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing. 

    By Dec. 1, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Large pharmas probe takeover of Horizon Therapeutics

    The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

    By Updated Nov. 30, 2022